VERNON, France, Aug. 8, 2023 /PRNewswire/ -- SYSNAV Healthcare announces that the European Medicines Agency (EMA) considers that for ambulant Duchenne Muscular Dystrophy (DMD) patients four years of ...
Sysnav Healthcare SA and Roche Holding AG entered a new collaboration to develop digital endpoints for use in clinical trials of therapies for a range of neuromuscular disorders. The alliance combines ...
Roche and Boehringer Ingelheim have both formed partnerships with tech companies this week to develop and deploy wearable biosensor technology for use in clinical trials and patient monitoring.
EMA opinion marks the first qualification of a digital outcome measure for use as a primary endpoint in pivotal drug trials SV95C is an objective, real-world digital ambulation measure of top ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results